沙美特罗替卡松粉吸入剂治疗50例中、重度儿童哮喘的疗效

目的 :观察沙美特罗替卡松粉吸入剂在儿童中、重度哮喘治疗中的疗效、安全性。方法 :将 80例中、重度哮喘病儿分成沙美特罗替卡松粉吸入剂治疗组 (治疗组 )和氟替卡松治疗组 (对照组 )。治疗组 5 0例 ,5～ 11a给予沙美特罗替卡松粉吸入剂 5 0μg / 10 0 μg·次 - 1(沙美特罗 5 0 μg,氟替卡松10 0 μg) ,bid。 12～ 14a给予沙美特罗替卡松粉吸入剂 5 0 μg/ 2 5 0 μg·次 - 1,bid。氟替卡松治疗组(对照组 ) 30例 ,5～ 11a给予氟替卡松 12 5 μg·次 - 1,bid。 12～ 14a给予氟替卡松 2 5 0 μg·次 1,tid。2组均连用 6mo ,按需使用沙丁胺醇。结果 :2组平均早、晚最大呼气峰流速值 (PEFam ,PEFpm ) ,需使用沙丁胺醇的日数在 8wk内有显著差异 ,自我评价在 4wk内有显著差异 ,症状评分在 3mo内有显著差异。 2组各有 1例咽部不适 ,经处理后缓解。结论 :沙美特罗替卡松粉吸入剂在儿童中、重度哮喘治疗中具良好的有效性、安全性。

Therapeutic effect of salmeterol xinafoate and fluticasone propionate powder for inhalation in treatment of 50 moderate and severe asthma children

AIM: To evaluate the clinical efficacy and safety of salmeterol xinafoate and fluticasone propionate in the treatment of moderate and severe asthma children. METHODS: Eighty sick children with moderate and severe asthma were randomly divided into two groups. These children in the treatment group (n=50) were given salmeterol xinafoate and fluticasone propionate, 50 μg/ 100 μg, bid in the patients aged 5 to 11 a and 50 μg/ 250 μg, bid in those aged 12 to 14 a, respectively. These children in the control group (n=30) were given fluticasone propionate (flixotide) 125 μg, bid in the patients aged 5 to 11 a and 250 μg in those aged 12 to 14 a, respectively. RESULTS: There was significant difference in PEFam, PEFpm and the days of using salbutamol after 8 wk treatment in two groups (P <0.05). Self-assessment in two groups had also significant difference after 4 wk treatment (P <0.05). Asthma symptom scores were improved significantly after 3 mo treatment (P< 0.05). Each group had one patient suffering pharynx malaise who recovered quickly after proper treatments. CONCLUSION: Salmeterol xinafoate and fluticasone propionate possesses good effectiveness, safety and well tolerance in the treatment of moderate and severe asthma children.